Livealth Biopharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-11-2024
- Paid Up Capital ₹ 0.10 M
as on 15-11-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.80 M
as on 15-11-2024
- Revenue 52.05%
(FY 2023)
- Profit 107.55%
(FY 2023)
- Ebitda 131.67%
(FY 2023)
- Net Worth 87.04%
(FY 2023)
- Total Assets 11.98%
(FY 2023)
About Livealth Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.80 M.
Bhavesh Kanabar and Sanjay Patil serve as directors at the Company.
- CIN/LLPIN
U24296MH2016PTC274406
- Company No.
274406
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Mar 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Livealth Biopharma Private Limited offer?
Livealth Biopharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Syrup, Eye Drops, Injectable Products, Child and Baby Care Products, Baby Care Products, Psoriasis Ointment, Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Pharma Ingredients & Raw Materials.
Who are the key members and board of directors at Livealth Biopharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhavesh Kanabar  | Director | 15-Mar-2016 | Current |
| Sanjay Patil | Director | 15-Mar-2016 | Current |
Financial Performance of Livealth Biopharma.
Livealth Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 52.05% increase. The company also saw a substantial improvement in profitability, with a 107.55% increase in profit. The company's net worth Soared by an impressive increase of 87.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Livealth Biopharma?
In 2023, Livealth Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nirali Ruparel Gurwada Couture House Private LimitedActive 9 years 23 daysBhavesh Kanabar is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Jan 2019 | ₹7.80 M | Open |
How Many Employees Work at Livealth Biopharma?
Unlock and access historical data on people associated with Livealth Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Livealth Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Livealth Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
